Metformin and Cancer: Is This the End?

Emily J. Gallagher; Nathan G. Kase; Nina A. Bickell; Derek LeRoith

doi:10.1016/j.eprac.2022.06.005

Metformin and Cancer: Is This the End?

Emily J. Gallagher, Nathan G. Kase, Nina A. Bickell, Derek LeRoith

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	832-834
Number of pages	3
Journal	Endocrine Practice
Volume	28
Issue number	8
DOIs	https://doi.org/10.1016/j.eprac.2022.06.005
State	Published - Aug 2022

Keywords

MA.32
breast cancer
insulin resistance
metformin

Access to Document

10.1016/j.eprac.2022.06.005

Cite this

@article{158b89a206f04c5fb9179b0a0640a8c1,

title = "Metformin and Cancer: Is This the End?",

keywords = "MA.32, breast cancer, insulin resistance, metformin",

author = "Gallagher, {Emily J.} and Kase, {Nathan G.} and Bickell, {Nina A.} and Derek LeRoith",

note = "Funding Information: E.J.G. received research support from the National Institutes of Health (NIH)/National Cancer Institute (NCI) K08CA190770, Department of Medicine, and Tisch Cancer Institute at Mount Sinai. N.G.K. received research support from the Lifetime Career Award, Icahn School of Medicine at Mount Sinai. N.A.B. received funding from NIH/NCI P30CA196521, R01CA242748, and U01CA265739, NIH/National Heart Lung and Blood Institute (NHLBI) OT2HL156812, NIH/National Institute of Minority Health and Health Disparities (NIMHD) R01MD017508. N.A.B. and D.L.R. received funding from NIH/NCI R01CA171558. D.L.R. received research support from NIH/NCI R01CA200553 and R01CA128799. E.J.G. is a consultant for Novartis, SynDevRx, and Seagen. D.L.R. has served on advisory boards for Mannkind and AstraZeneca. The other authors have no multiplicity of interest to disclose. Funding Information: E.J.G. received research support from the National Institutes of Health (NIH)/National Cancer Institute (NCI) K08CA190770, Department of Medicine, and Tisch Cancer Institute at Mount Sinai. N.G.K. received research support from the Lifetime Career Award, Icahn School of Medicine at Mount Sinai. N.A.B. received funding from NIH/NCI P30CA196521, R01CA242748, and U01CA265739, NIH/National Heart Lung and Blood Institute (NHLBI) OT2HL156812, NIH/National Institute of Minority Health and Health Disparities (NIMHD) R01MD017508. N.A.B. and D.L.R. received funding from NIH/NCI R01CA171558. D.L.R. received research support from NIH/NCI R01CA200553 and R01CA128799. ",

year = "2022",

month = aug,

doi = "10.1016/j.eprac.2022.06.005",

language = "English",

volume = "28",

pages = "832--834",

journal = "Endocrine Practice",

issn = "1530-891X",

publisher = "Elsevier BV",

number = "8",

}

TY - JOUR

T1 - Metformin and Cancer

T2 - Is This the End?

AU - Gallagher, Emily J.

AU - Kase, Nathan G.

AU - Bickell, Nina A.

AU - LeRoith, Derek

N1 - Funding Information: E.J.G. received research support from the National Institutes of Health (NIH)/National Cancer Institute (NCI) K08CA190770, Department of Medicine, and Tisch Cancer Institute at Mount Sinai. N.G.K. received research support from the Lifetime Career Award, Icahn School of Medicine at Mount Sinai. N.A.B. received funding from NIH/NCI P30CA196521, R01CA242748, and U01CA265739, NIH/National Heart Lung and Blood Institute (NHLBI) OT2HL156812, NIH/National Institute of Minority Health and Health Disparities (NIMHD) R01MD017508. N.A.B. and D.L.R. received funding from NIH/NCI R01CA171558. D.L.R. received research support from NIH/NCI R01CA200553 and R01CA128799. E.J.G. is a consultant for Novartis, SynDevRx, and Seagen. D.L.R. has served on advisory boards for Mannkind and AstraZeneca. The other authors have no multiplicity of interest to disclose. Funding Information: E.J.G. received research support from the National Institutes of Health (NIH)/National Cancer Institute (NCI) K08CA190770, Department of Medicine, and Tisch Cancer Institute at Mount Sinai. N.G.K. received research support from the Lifetime Career Award, Icahn School of Medicine at Mount Sinai. N.A.B. received funding from NIH/NCI P30CA196521, R01CA242748, and U01CA265739, NIH/National Heart Lung and Blood Institute (NHLBI) OT2HL156812, NIH/National Institute of Minority Health and Health Disparities (NIMHD) R01MD017508. N.A.B. and D.L.R. received funding from NIH/NCI R01CA171558. D.L.R. received research support from NIH/NCI R01CA200553 and R01CA128799.

PY - 2022/8

Y1 - 2022/8

KW - MA.32

KW - breast cancer

KW - insulin resistance

KW - metformin

UR - http://www.scopus.com/inward/record.url?scp=85133874340&partnerID=8YFLogxK

U2 - 10.1016/j.eprac.2022.06.005

DO - 10.1016/j.eprac.2022.06.005

M3 - Comment/debate

C2 - 35724834

AN - SCOPUS:85133874340

SN - 1530-891X

VL - 28

SP - 832

EP - 834

JO - Endocrine Practice

JF - Endocrine Practice

IS - 8

ER -